New insulin delivery devices may provide options for diabetic nurses

No one — not even nurses — likes needles. But injectable insulin has been the mainstay of diabetes treatment for years, leaving few choices for nurses with advanced disease.

Two new insulin delivery devices may soon change all that. Oral-lyn, an oral spray delivered via an inhaler-type device, and Afrezza, an inhaled form of insulin, both show promise in Phase III studies. Both controlled blood sugars at least as well as injectable insulin, while causing less weight gain. Both also have the potential to cause fewer episodes of hypoglycemia.

That’s potentially big news for diabetics everywhere. (With any luck, both products could be on the market within two years.) The faster-acting forms of insulin may be a particular boon for diabetic nurses who struggle to maintain regular eating and activity levels in light of ever-changing work schedules.


, , , , ,

Jennifer Fink, RN, BSN

Jennifer is a professional freelance writer with over eight years experience as a hospital nurse. She has clinical experience in adult health, including med-surg, geriatrics and transplant; she also has a particular interest in women’s health and cancer care. Jennifer has written a variety of health and parenting articles for national publications.

Post a Comment

You must or register to post a comment.

One Response to New insulin delivery devices may provide options for diabetic nurses

  1. tc2000chartreader

    Thank you for taking the time to pass on the inportant information from this past weekend’s LA Times Health.

    There are a few things that the article did not make clear:
    1. Generex’s Oral-lyn not only caused less weight gain than Afrezza and injectable insulin, they actually lost weight and lowered their BMI. Much more compliant with the body’s natural insulin.
    2. Generex’s Oral-lyn has been granted FDA Treatment IND status. So it is available to patients with serious or life-threatening Type 1 or Type 2 diabetes mellitus, with no satisfactory alternative therapy available for treatment of diabetes, and who are not eligible to participate in the ongoing pivotal clinical trial (Protocol GEN-084-OL). Afrezza does not have that status.

    Please review the clinical trials site for additional information on how to get some of your patients involved.

    For anyone else that wants to read the full LA Times articles, it is here.,0,4580637.story